Study guide

9.2 Therapeutic Monitoring & Laboratory Interpretation

DHA Pharmacist Licensing Assessment PHO5481

Track your progress as you read

Finished sections get a check mark.

1 Exam Overview & Licensing Pathway

1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan

2 Cardiovascular Pharmacology

2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents

3 Endocrine & Metabolic Pharmacology

3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents

4 Anti-Infective Pharmacology

4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars

5 CNS, Psychiatric & Pain Pharmacology

5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine

6 Respiratory, GI & Hematology Pharmacology

6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents

7 Pharmaceutical Care: Cardiometabolic Disease

7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management

8 Pharmaceutical Care: Respiratory, Rheumatology & Infection

8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship

9 Counseling, Monitoring & Special Populations

9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making

10 Pharmaceutical Calculations I

10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation

11 Pharmaceutical Calculations II

11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents

12 UAE Pharmacy Law & Regulation

12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity

13 Controlled Drugs, Ethics & Pharmacovigilance

13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal

14 Pharmacokinetics I: ADME

14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination

15 Pharmacokinetics II: Kinetics, Dosing & TDM

15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring

16 OTC Medicines & Self-Care

16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin

17 Medication Safety

17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition

18 Sterile & Nonsterile Compounding

18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding

19 Pharmaceutics, Biopharmaceutics & Toxicology

19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes

20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics

20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics

9.2 Therapeutic Monitoring & Laboratory Interpretation

Key Takeaways Explain This Topic AI

Cockcroft-Gault creatinine clearance = (140 − age) × weight (× 0.85 for women) ÷ (72 × serum creatinine in mg/dL) — it remains the basis of most renal drug-dosing thresholds

Draw trough levels immediately before the next dose; digoxin samples must be at least 6 hours post-dose and lithium 12 hours post-dose to be interpretable

Key drug targets: digoxin 0.5–2.0 ng/mL, lithium 0.6–1.0 mmol/L, phenytoin 10–20 mg/L (correct for low albumin), vancomycin AUC/MIC 400–600, theophylline 10–20 mg/L

Common renal dose triggers: metformin (stop if eGFR <30), DOACs, gabapentin and digoxin — check renal function before dispensing

Potassium above 6.0 mmol/L, INR above 5, or digoxin toxicity symptoms are critical values requiring urgent action, documented communication and read-back

Last updated: August 2026

Reference Ranges a Pharmacist Must Interpret

The exam tests recognition of abnormal results and their medication implications, not just recall of numbers. Core ranges:

Test Typical reference / target Pharmacist relevance

HbA1c (glycated haemoglobin) Diabetes diagnosis ≥6.5%; glycaemic target often <7% (individualised) Reflects ~3 months of glycaemic control; drives therapy escalation

Fasting lipid panel Total cholesterol desirable <5.0 mmol/L; triglycerides <1.7 mmol/L; LDL goals are risk-based (e.g. <1.8 mmol/L in very-high-risk patients) Statin monitoring and cardiovascular risk management

ALT / AST (liver enzymes) Roughly <40 U/L (lab-dependent) >3× upper limit of normal with symptoms triggers review of hepatotoxic drugs

TSH (thyroid-stimulating hormone) ~0.4–4.0 mIU/L Guides levothyroxine dose; recheck ~6 weeks after a dose change

INR (international normalised ratio) Warfarin target 2.0–3.0 for most indications; 2.5–3.5 for mechanical mitral valves Dose adjustment and bleeding-risk assessment

  • Serum potassium 3.5–5.0 mmol/L ACE inhibitors, ARBs, spironolactone raise it; diuretics lower it
  • Serum sodium 135–145 mmol/L SSRIs and diuretics can cause hyponatraemia, especially in older adults
  • Therapeutic Drug Monitoring (TDM)

Trough samples are drawn immediately before the next dose ; peak samples are drawn after distribution is complete. Levels are only meaningful at steady state (about five half-lives) unless toxicity is suspected.

Peak timing is drug-specific. For a conventional-dose aminoglycoside given as a 30-minute infusion, the peak is taken about 30 minutes after the infusion ends. For vancomycin under AUC-guided dosing, two levels (peak and trough) within the same interval allow Bayesian or first-order AUC estimation. Samples drawn before steady state must be interpreted with caution: they can only exclude gross overdose or confirm accumulation, never confirm that the maintenance regimen is correct. When a dose is changed, wait roughly five half-lives before re-sampling — longer in renal impairment, where half-lives of renally cleared drugs such as digoxin and gentamicin are substantially prolonged.

Drug Target range Sampling notes

Digoxin 0.5–2.0 ng/mL (heart failure target 0.5–0.9) Sample ≥6 hours post-dose , ideally pre-dose; hypokalaemia, hypomagnesaemia, hypercalcaemia and renal impairment potentiate toxicity

Lithium 0.6–1.0 mmol/L (maintenance) 12-hour post-dose sample; toxicity >1.5 mmol/L; dehydration, NSAIDs, ACE inhibitors and thiazides raise levels

Phenytoin 10–20 mg/L Correct for hypoalbuminaemia : adjusted level = measured ÷ [(0.2 × albumin in g/dL) + 0.1]; saturable kinetics mean small dose increases can cause large level rises

Vancomycin AUC₂₄/MIC 400–600 mg·h/L for serious MRSA infection Trough 15–20 mg/L was the historical surrogate; AUC-guided dosing is now preferred

Gentamicin Once-daily dosing: trough <1 mg/L; conventional dosing: peak 5–10 mg/L, trough <2 mg/L High troughs signal accumulation and nephro-/ototoxicity risk

Theophylline 10–20 mg/L Narrow therapeutic index; levels rise with ciprofloxacin, erythromycin and cimetidine, and fall in smokers

Interpreting Liver Enzyme Patterns

When reviewing liver function tests (LFTs) , look at the pattern, not just the magnitude. A hepatocellular pattern (ALT/AST markedly raised, alkaline phosphatase relatively spared) points to hepatocyte injury and triggers review of hepatotoxic drugs such as paracetamol overdose, statins, isoniazid, or valproate. A cholestatic pattern (alkaline phosphatase and bilirubin predominating) suggests impaired bile flow, as with co-amoxiclav or anabolic steroids. A rise in ALT or AST beyond three times the upper limit of normal accompanied by symptoms (nausea, jaundice, dark urine) is a standard threshold for stopping or reviewing a suspect drug. Isolated, mild, asymptomatic transaminase rises on statins are common and usually do not require discontinuation.

Renal Function Assessment and Dose Triggers

The Cockcroft-Gault equation estimates creatinine clearance (CrCl) :

CrCl (mL/min) = [(140 − age) × weight in kg × (0.85 if female)] ÷ (72 × serum creatinine in mg/dL)

Drug dosing references were historically validated against CrCl, whereas laboratories report eGFR (estimated glomerular filtration rate); be alert that the two can differ, especially at extremes of body weight. Classic renal dose-adjustment triggers:

Metformin — contraindicated if eGFR <30 mL/min/1.73 m²; review risks and benefits at 30–45 (lactic acidosis risk).

Direct oral anticoagulants (DOACs) — dabigatran is contraindicated at CrCl <30 mL/min; apixaban, rivaroxaban and edoxaban need dose reduction or avoidance at defined renal thresholds.

Gabapentin — reduce dose and frequency as CrCl falls; accumulation causes sedation and myoclonus.

Digoxin — reduce maintenance dose in renal impairment and monitor levels.

Others frequently examined: enoxaparin (reduce at CrCl <30) and many renally cleared antibiotics.

Trends vs Single Values

A single result should be interpreted against the baseline and the trend , the timing of the sample, and the clinical picture. An HbA1c falling from 9% to 7.5% is progress even though it remains above target; a potassium creeping from 4.2 to 5.4 over three visits on spironolactone is more concerning than one isolated 5.2. Never act on a laboratory number alone when a repeat sample or clinical review would change the decision.

Critical Values Requiring Urgent Action

Recognise results that cannot wait for routine follow-up:

Potassium >6.0 mmol/L (or <3.0 mmol/L) — risk of life-threatening arrhythmia; urgent medical assessment.

INR >5 — high bleeding risk; withhold warfarin and refer urgently, immediately if any bleeding.

Digoxin toxicity — nausea, vomiting, anorexia, blurred or yellow-tinted vision, confusion, or new arrhythmia, especially with a level >2.0 ng/mL: withhold and refer.

The pharmacist must document and communicate critical values promptly to the prescriber, using structured communication with read-back (the receiver repeats the value back to confirm accuracy), and record who was informed, when, and the response.